Ligand id: 7540

Name: brodalumab

No information available.
Summary of Clinical Use
Brodalumab was first approved in Japan (2016), and by the US FDA for plaque psoriasis the following year. Regulatory decisions are pending elsewhere. Clinical trials for the treatment of psoriatic arthritis (Phase III), moderate to severe plaque psoriasis (Phase III) and asthma (Phase II) are ongoing. Encouraging results from a Phase II study have been reported [4].
Mechanism Of Action and Pharmacodynamic Effects
The IL-17 pathway is an established driver of psoriasis pathogenesis [1-3]. Brodalumab is an anti-IL17RA monoclonal antibody. Competitive inhibition of IL-17RA by brodalumab in psoriatic skin leads to rapid dose-dependent transcriptomal normalisation, ie genes up-regulated in psoraisis are returned to normal levels of transcription. This is accompanied by decreased keratinocyte hyperplasia and leukocyte infiltration, which are effects indicating a positive clinical response [6].